Literature DB >> 9212099

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

S M Kang1, D B Schneider, Z Lin, D Hanahan, D A Dichek, P G Stock, S Baekkeskov.   

Abstract

Fas ligand is believed to mediate immune privilege in a variety of tissues, including the eye, testis, and a subset of tumors. We tested whether expression of Fas ligand on pancreatic islets either following adenoviral or germline gene transfer could confer immune privilege after transplantation. Islets were infected with an adenoviral vector containing the murine Fas ligand cDNA (AdFasL), and were transplanted into allogenic diabetic hosts. Paradoxically, AdFasL-infected islets underwent accelerated neutrophilic rejection. The rejection was T cell and B cell independent and required Fas protein expression by host cells, but not on islets. Similarly, transgenic mice expressing Fas ligand in pancreatic beta cells developed massive neutrophilic infiltrates and diabetes at a young age. Thus, Fas ligand expression on pancreatic islets results in neutrophilic infiltration and islet destruction. These results have important implications for the development of Fas ligand-based immunotherapies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212099     DOI: 10.1038/nm0797-738

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  76 in total

Review 1.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

3.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Countering the 'counterattack' hypothesis.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

Review 5.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 6.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Characterization of a novel functional protein in the pancreatic islet: islet homeostasis protein regulation of glucagon synthesis in α cells.

Authors:  Seh-Hoon Oh; Houda Darwiche; Jae-Hyoung Cho; Thomas Shupe; Bryon E Petersen
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

Review 8.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 9.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

10.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.